ClinicalTrials.gg
CompletedNCT02022748Updated Jan 17, 2018Results posted

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

A Phase 1 interventional study of ticagrelor and ticagrelor in Kidney Failure, Chronic, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-17.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
408th of 638
27 · median 48
Started
2013
with 37 others
Phase 1
89 of 765
8 open now
Registered
346th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 408th largest by enrollment of the 638 interventional ones that give a count, is one of 38 that started in 2013, is one of 89 in phase 1, and was the 346th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.

Read the detailed description

This will be a single dose, randomised, open label, parallel group study conducted in the US to examine the Pharmacokinetics (PK), Pharmacodynamics (PD), safety, and tolerability of ticagrelor in end stage renal disease (ESRD) subjects on hemodialysis (HD) compared with healthy subjects with normal renal function. Up to a total of 30 male and female adult subjects aged 18 to 80 years (inclusive) with a weight of at least 50 kg and a body mass index between 18 and 40 kg/m2 (inclusive), will be dosed to assure that there will be 20 evaluable subjects (10 subjects on HD and in 10 healthy subjects with normal renal function (CrCL ≥90 mL/min). The normal renal function groups should have a similar distribution with respect to age, weight and gender. Subjects will be required to have an inpatient stay from the day prior to dosing until the 48-hour post-dose time-point to ensure that all PK samples are collected at the appropriate timepoints. The study will be conducted in two groups: Group A consisting of ESRD subjects on HD, Group B consisting of healthy subjects. A crossover design will be implemented for Group A subjects as follows: Group A subjects will be randomized into two sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. There will be washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Similarly in Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. There will be a washout period of at least 7 days between Period 1 and Period 2 in Sequence 2 as well. Treatment A and treatment B are defined as follows: Treatment A: subjects will be dosed with an oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session; • Treatment B: subjects will be dosed with an oral 90 mg ticagrelor tablet just prior to dialysis session.(NB: Treatment B dosing should occur within 5 minutes of dialysis start). Group B subjects (healthy subjects) with normal renal function (CrCL of ≥ 90 mL/min) will receive just an oral 90 mg ticagrelor referred to as treatment H. All doses will be administered in an open-label design.

03

Conditions studied

  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female aged 18 to 80 years (inclusive).
  • Normal renal function ( of ≥90 mL/min) or End Stage Renal Disease (ESRD) requiring hemodialysis.

Exclusion criteria

Exclusion Criteria:

  • Any indication for oral anticoagulant or anti treatment during study period. Must be off treatment for at least 3 weeks (low dose 81mg aspirin is allowed for hemodialysis subjects only).
  • Acute Coronary Syndrome (ACS) within past 12 months.
  • to ticagrelor (ie: active pathological bleeding, severe hepatic impairment, history of hemorrhagic stroke, allergic to ticagrelor).
  • Platelet count \<100000/μL, \<9g/dL
  • Blood donation within 90 days of dosing
  • Risk for bradycardia
  • drug within 30 days or 6 half-lives, whichever is longer, before dosing
  • Concomitant therapy with inhibitors/substrates with narrow therapeutic index,or strong CYP3A inducers 14 days before dosing until completion of the follow-up visit.
  • History of alcohol, drug, or substance abuse within the past year
  • laboratory abnormalities as judged by the investigator.
  • Increased bleeding risk including GI bleeding in past 30 days; history of intracranial, retroperitoneal, or spinal bleeding, recent major trauma within 30 days of dosing, Sustained uncontrolled hypertension, history of hemorrhagic disorders.
  • Pregnant or lactating females, or females of (ie, those who are not chemically or surgically sterilised or who are not ) who are not willing to use a medically accepted method of that is considered reliable in the judgment of the investigator throughout the duration of the study OR females who have a positive pregnancy test at Visit 1.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Sequence 1

    hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.

    Drug: ticagrelor

  • Experimental
    Sequence 2

    hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.

    Drug: ticagrelor

  • Experimental
    Treatment H

    Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment

    Drug: ticagrelor

Interventions

  • Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.

    Also known as: Brilinta

  • Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.

    Also known as: Brilinta

  • Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.

    Also known as: Brilinta

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Parameter Cmax of Ticagrelor

    Time frame: 0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose

  2. Pharmacokinetic Parameter Cmax of AR-C124910XX

    Time frame: 0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose

  3. Pharmacokinetic Parameter AUC0-∞ (Area Under the Plasma Concentration-time Curve From Time Zero to Infinity) of Ticagrelor

    Time frame: 0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose

  4. Pharmacokinetic Parameter AUC0-∞ of AR-C124910XX

    Time frame: 0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose

Secondary outcomes

  1. Pharmacokinetic Parameter t1/2 of Ticagrelor

    Time frame: 3 days

  2. Pharmacokinetic Parameter t1/2 of AR-C124910XX

    Time frame: 3 days

07

Results

Posted Sep 29, 2017

Participant flow

56 subjects signed ICF, 34 Hemodialysis (HD) subjects and 22 Healthy subjects (HS) at 2 study centers in the US. 27 subjects received treatment (14 HD and 13 HS). First patient signed ICF on 29 December 2013. Due to protocol amendment, the first patient was randomized 22 months later on 20 October 2015, last patient last visit was 09 May 2016.

Participant flow — Overall Study
MilestoneSequence 1 (AB)Sequence 2 (BA)Treatment H
Started8613
Subject who started treatment8613
Subjects who completed treatment7413
Completed7413
Not completed120
Withdrew: Adverse event110
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryPharmacokinetic Parameter Cmax of Ticagrelor
Time frame:
0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter Cmax of Ticagrelor
ng/mLTreatment ATreatment BTreatment H
Pharmacokinetic Parameter Cmax of Ticagrelor560.32 ± 54.0598.35 ± 47.9370.76 ± 37.3
Statistical analysis
  • Treatment A vs Treatment H · Ratio of geometric least square means: 151.13 · 90% CI 112.03 to 203.86Treatment H is the reference treatment.
  • Treatment B vs Treatment H · Ratio of geometric least square means: 161.38 · 90% CI 122.52 to 212.58Treatment H is the reference treatment.
  • Treatment A vs Treatment B · Ratio of geometric least square means: 90.10 · 90% CI 78.07 to 103.98A linear mixed model with sequence, period, and treatment as fixed effects, and subject-within-sequence as a random effect, was used to analyze the natural log-transformed values of the PK parameters. Treatment B is the reference treatment.
PrimaryPharmacokinetic Parameter Cmax of AR-C124910XX
Time frame:
0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter Cmax of AR-C124910XX
ng/mLTreatment ATreatment BTreatment H
Pharmacokinetic Parameter Cmax of AR-C124910XX130.82 ± 38.3152.25 ± 54.3111.73 ± 60.0
Statistical analysis
  • Treatment A vs Treatment H · Ratio of geometric least square means: 117.09 · 90% CI 84.51 to 162.22Treatment H is the reference treatment.
  • Treatment B vs Treatment H · Ratio of geometric least square means: 136.27 · 90% CI 95.38 to 194.70Treatment H is the reference treatment.
  • Treatment A vs Treatment B · Ratio of geometric least square means: 82.29 · 90% CI 68.43 to 98.96A linear mixed model with sequence, period, and treatment as fixed effects, and subject-within-sequence as a random effect, was used to analyze the natural log-transformed values of the PK parameters. Treatment B is the reference treatment.
PrimaryPharmacokinetic Parameter AUC0-∞ (Area Under the Plasma Concentration-time Curve From Time Zero to Infinity) of Ticagrelor
Time frame:
0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic Parameter AUC0-∞ (Area Under the Plasma Concentration-time Curve From Time Zero to Infinity) of Ticagrelor
ng*h/mLTreatment ATreatment BTreatment H
Pharmacokinetic Parameter AUC0-∞ (Area Under the Plasma Concentration-time Curve From Time Zero to Infinity) of Ticagrelor3015.1 ± 54.23256.1 ± 52.52188.8 ± 22.6
Statistical analysis
  • Treatment A vs Treatment H · Ratio of geometric least square means: 137.75 · 90% CI 105.70 to 179.52Treatment H is the reference treatment.
  • Treatment B vs Treatment H · Ratio of geometric least square means: 148.76 · 90% CI 115.07 to 192.32Treatment H is the reference treatment.
  • Treatment A vs Treatment B · Ratio of geometric least square means: 90.35 · 90% CI 77.55 to 105.27A linear mixed model with sequence, period, and treatment as fixed effects, and subject-within-sequence as a random effect, was used to analyze the natural log-transformed values of the PK parameters. Treatment B is the reference treatment.
PrimaryPharmacokinetic Parameter AUC0-∞ of AR-C124910XX
Time frame:
0, 1, 2, 4, 6, 12, 24, 36, 48 hours post-dose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic Parameter AUC0-∞ of AR-C124910XX
ng*h/mLTreatment ATreatment BTreatment H
Pharmacokinetic Parameter AUC0-∞ of AR-C124910XX1127.8 ± 39.31144.2 ± 36.21000.4 ± 33.2
Statistical analysis
  • Treatment A vs Treatment H · Ratio of geometric least square means: 112.73 · 90% CI 88.61 to 143.42Treatment H is the reference treatment.
  • Treatment B vs Treatment H · Ratio of geometric least square means: 114.37 · 90% CI 91.19 to 143.45Treatment H is the reference treatment.
  • Treatment A vs Treatment B · Ratio of geometric least square means: 93.13 · 90% CI 80.31 to 108.00A linear mixed model with sequence, period, and treatment as fixed effects, and subject-within-sequence as a random effect, was used to analyze the natural log-transformed values of the PK parameters. Treatment B is the reference treatment.
SecondaryPharmacokinetic Parameter t1/2 of Ticagrelor
Time frame:
3 days
Reported as:
Mean · hour
Pharmacokinetic Parameter t1/2 of Ticagrelor
hourTreatment ATreatment BTreatment H
Pharmacokinetic Parameter t1/2 of Ticagrelor8.303 ± 1.2508.691 ± 2.2988.412 ± 1.248
Statistical analysis
  • Treatment A vs Treatment H · Mean difference (net): -0.11 · 90% CI -0.97 to 0.75Treatment A - Treatment H.
  • Treatment B vs Treatment H · Mean difference (net): 0.28 · 90% CI -0.96 to 1.52Treatment B - Treatment H.
  • Treatment A vs Treatment B · Difference of least square means: -0.36 · 90% CI -1.73 to 1.02A linear mixed model with sequence, period, and treatment as fixed effects, and subject-within-sequence as a random effect, was used to analyze the natural log-transformed values of the PK parameters. Treatment A - Treatment B.
SecondaryPharmacokinetic Parameter t1/2 of AR-C124910XX
Time frame:
3 days
Reported as:
Mean · hour
Pharmacokinetic Parameter t1/2 of AR-C124910XX
hourTreatment ATreatment BTreatment H
Pharmacokinetic Parameter t1/2 of AR-C124910XX7.574 ± 2.0797.596 ± 1.7578.644 ± 2.414
Statistical analysis
  • Treatment A vs Treatment H · Mean difference (net): -1.07 · 90% CI -2.62 to 0.48Treatment A - Treatment H.
  • Treatment B vs Treatment H · Mean difference (net): -1.05 · 90% CI -2.46 to 0.37Treatment B - Treatment H.
  • Treatment A vs Treatment B · Difference of least square means: -0.50 · 90% CI -1.27 to 0.27A linear mixed model with sequence, period, and treatment as fixed effects, and subject-within-sequence as a random effect, was used to analyze the natural log-transformed values of the PK parameters. Treatment A - Treatment B.

Adverse events

Collected over Starting from the date of first dose of study medication to follow-up (5-10 days post discharge unit). For HD Subjects, events that occurred during the washout or follow-up periods are attributed to the previous treatment taken.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/12 (0%)2/12 (16.7%)
Treatment B—1/13 (7.7%)3/13 (23.1%)
Treatment H—0/13 (0%)2/13 (15.4%)
Most frequent serious events
Most frequent serious events
EventTreatment ATreatment BTreatment H
Thoracic vertebral fractureInjury, poisoning and procedural complications0/121/130/13
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTreatment ATreatment BTreatment H
Fluid overloadMetabolism and nutrition disorders1/120/130/13
DizzinessNervous system disorders1/120/130/13
BronchospasmRespiratory, thoracic and mediastinal disorders1/120/130/13
NauseaGastrointestinal disorders1/121/130/13
HeadacheNervous system disorders0/120/131/13
MigraineNervous system disorders0/121/130/13
Restless legs syndromeNervous system disorders0/120/131/13
ConstipationGastrointestinal disorders0/121/130/13
VomitingGastrointestinal disorders0/121/130/13
OsteoporosisMusculoskeletal and connective tissue disorders0/121/130/13

Baseline characteristics

All 14 randomized HD subjects after eligibility re-assessment (8 in Sequence 1 (AB) and 6 in Sequence 2 (BA)) and 13 eligibile HS are used for baseline analysis.

Age, Continuous
Age, Continuous(years)HD SubjectsHS SubjectsTotal
Mean50.6 ± 12.543.8 ± 10.447.3 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)HD SubjectsHS SubjectsTotal
Female235
Male121022
Weight
Weight(kg)HD SubjectsHS SubjectsTotal
Mean85.1 ± 18.389.0 ± 16.287.0 ± 17.1
BMI
BMI(kg/m^2)HD SubjectsHS SubjectsTotal
Mean27.77 ± 4.1828.27 ± 3.7528.01 ± 3.91
08

Study locations

2 sites
  • Research Site
    Lakewood, Colorado 80228, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. PubMed 35224730 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in May 2016, 28 months.

Results were first posted in Sep 2017, 1 year 4 months after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 28 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2013
First posted
Dec 30, 2013
StartActual
Dec 29, 2013
Primary completionActual
May 9, 2016
CompletionActual
May 9, 2016
Results first posted
Sep 29, 2017
Last update
Jan 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02022748
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 30, 2013
Start date
Dec 29, 2013
Primary completion
May 9, 2016
Completion
May 9, 2016
Results posted
Sep 29, 2017
Last update
Jan 17, 2018

Study contacts

Jolene K Berg, MD
principal investigator · DaVita Clinical Research, Minneapolis, MN

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion